Psychiatr. praxi. 2020;21(2):78-82 | DOI: 10.36290/psy.2020.014

Treatment possibilities of pharmaco-resistant schizofrenie in common clinical practice

prof. MUDr. Eva Češková, CSc.1,2,3, MUDr. Martin Hýža, Ph.D.2,3
1 Psychiatrická klinika LF MU a FN Brno
2 KPN LF Univerzity Ostrava
3 Oddělení psychiatrie, FN Ostrava

The paper is focused on available therapeutic approaches to schizophrenia in common clinical practice. The literature and clinical experience stress the exclusion of pseudoresistance, caused mainly by nonadherence. The gold standard is clozapine. Further possibilities include augmentation and combination of antipsychotics; however, for these strategies there is not enough evidence and results are inconsistent. Augmentation is aimed mostly on persistent and dominant symptoms (depressive and negative symptoms, cognitive deficit). The most frequently used combination is combination of clozapine with an antipsychotic with complementary pharmacological profile.

Keywords: pharmaco‑resistant schizophrenia, clozapine, augmentation, combination of antipsychotics.

Published: June 29, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Češková E, Hýža M. Treatment possibilities of pharmaco-resistant schizofrenie in common clinical practice. Psychiatr. praxi. 2020;21(2):78-82. doi: 10.36290/psy.2020.014.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Howes OD, Rob McCutcheon R, Agid O, et al. Treatment‑resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. Am J Psychiatry 2017; 174: 216-229. Go to original source... Go to PubMed...
    2. Češková E, Šilhán P, Kacířová I, et al. Terapeutické monitorování léčiv v psychiatrii. V: Doporučené postupy psychiatrické péče Psychiatrické společnosti ČLS JEP. www.psychiatrie.cz
    3. Mayerová, M, Turjap M, Ustohal L, et al. Terapeutické monitorování plazmatických koncentrací olanzapinu a klozapinu. Čes a slov Psychiatrie 2016; 112: 177-187.
    4. Huhn M, Nikolakopoulou A, Schneider‑Toma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi‑episode schizophrenia: A systematic review and network meta‑analysis. Lancet 2019; 394: 939-951. Go to original source...
    5. Fleischhacker W, Galderisi S, Laszlovszky I, et al. The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS‑derived factors. Eur Psychiatry 2019; 58: 1-9. Go to original source...
    6. Cerveri G, Gesi C, Mencacci C. Pharmacological treatment of negative symptoms in schizophrenia: update and proposal of a clinical algorithm. Neuropsychiatr Dis Treat 2019; 15: 1525-1535. Go to original source...
    7. Mohr P, Masopust J. Lurasion: Profil antipsychotika druhé generace. Psychiatrie 2019; 23 :197-204.
    8. Howes OD, Vergunst F, Gee S, et al. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry 2012; 201: 481-485. Go to original source... Go to PubMed...
    9. Samara MT, Dold M, Gianatsi M, et al. Efficacy, acceptability, and tolerability of antipsychotics in treatment‑resistant schizophrenia: A network meta‑analysis. JAMA Psychiatry 2016; 73: 199-210. Go to original source...
    10. Remington G, Agid O, Foussias G, et al. Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold? Psychopharmacology (Berl) 2013; 225: 505-518. Go to original source...
    11. Masuda T, Misawa F, Takase M, et al. Association with hospitalization and all‑cause discontinuation among patients with schizophrenia on clozapine vs other oral second‑generation antipsychotics. A systematic review and meta‑analysis of cohort studies. JAMA Psychiatry 2019: 76: 1052-1062. Go to original source...
    12. Agid O, Arenovich T, Sajeev G, et al. An algorithm‑based approach to first‑episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry 2011;72: 1439-1444. Go to original source... Go to PubMed...
    13. Wimberley T, MacCabe JH, Laursen TM, et al. Mortality and self‑harm in association with clozapine in treatment‑resistant schizophrenia. Am J Psychiatry 2017;174: 990-998. Go to original source... Go to PubMed...
    14. Citrome L. Unmet needs in the treatment of schizophrenia: New targets to help different symptom domains. J Clin Psychiatry 2014; 75 (Suppl 1): 21-26. Go to original source... Go to PubMed...
    15. Barnes TR, Drake R, Paton C, et al. Evidence‑based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2020; 34: 3-78. Go to original source... Go to PubMed...
    16. Correll CU, Rubio JM, Inczedy‑Farkas G et al. Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: Systematic overview and quality appraisal of the meta‑analytic evidence. JAMA Psychiatry 2017; 74: 675-684. Go to original source...
    17. Ceskova E. Pharmacological strategies for the management of comorbid depression and schizophrenia. Expert Opin Pharmacother 2020; 21: 459-465. Go to original source... Go to PubMed...
    18. Raboch J. Duševní zdraví a životní styl: Psychiatrie životním stylem Edice postgraduální medicíny, 2019, s. 296.
    19. Stubbs B, Vancampfort D, Hallgren M, et al. EPA guidance on physical activity as a treatment for severe mental illness: a meta‑review of the evidence and Position Statement from the European Psychiatric Association (EPA), supported by the International Organization of Physical Therapists in Mental Health (IOPTMH). Eur Psychiatry 2018; 54: 124-144. Go to original source...
    20. Cuéllar‑Barboza AB, Sánchez‑Ruiz JA, Corral PM. Use of omega-3 polyunsaturated fatty acids as augmentation therapy in treatment‑resistant schizophrenia. Prim Care Companion CNS Disord 2017;19: 10.4088/PCC.16l02040. Go to original source...
    21. Ali SA, Mathur N, Malhotra AK, et al. Electroconvulsive therapy and schizophrenia: A systematic review. Mol Neuropsychiatry. 2019; 5(2): 75-83. Go to original source...
    22. Guo Q, Li C, Wang J. Updated review on the clinical use of repetitive transcranial magnetic stimulation in psychiatric disorders. Neurosci Bull 2017; 33(6): 747-756. Go to original source... Go to PubMed...
    23. Dougall N, Maayan N, Soares‑Weiser K, et al. Transcranial magnetic stimulation for schizophrenia. Schizophr Bull. 2015; 41: 1220-1222. Go to original source... Go to PubMed...
    24. Prikryl R, Ustohal L, Prikrylova Kucerova H, et al. A detailed analysis of the effect of repetitive transcranial magnetic stimulation on negative symptoms of schizophrenia: a double‑blind trial. Schizophr Res 2013; 149(1-3): 167-173. Go to original source...
    25. Burns AM, Erickson DH, Brenner CA. Cognitive‑behavioral therapy for
    26. Burns AMN, Erickson DH, Brenner CA. Cognitive-behavioral therapy for medication‑resistant psychosis: a meta‑analytic review. Psychiatr Serv 2014; 65(7): 874-880. Go to original source... Go to PubMed...
    27. van der Gaag M, Valmaggia LR, Smit F. The effects of individually tailored formulation‑based cognitive behavioural therapy in auditory hallucinations and delusions: a meta‑analysis. Schizophr Res 2014; 156(1):30-37. Go to original source...
    28. Morrison AP, Pyle M, Gumley A, et al. Cognitive behavioural therapy in clozapine‑resistant schizophrenia (FOCUS): an assessor‑blinded, randomised controlled trial. Lancet Psychiatry. 2018; 5(8): 633-643. Go to original source...
    29. Sušilová L, Češková E. Monoterapie a kombinace antipsychotik u pacientů hospitalizovaných s diagnózou schizofrenie ve FN Brno. Čes a slov Psychiatr 2013;109: 122-127.
    30. Davis RE, Correll CU. ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes. Expert Rev Neurother 2016; 16: 601-114. Go to original source... Go to PubMed...
    31. Ceskova E, Silhan P. Novel treatment options in depression and psychosis. Neuropsychiatr Dis Treat 2018; 14: 741-747. Go to original source...
    32. Leweke F M, Mueller J K, Lange B, Rohleder C. Therapeutic potential of cannabinoids in psychosis. 2016; 79: 604-612.

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.